Results 121 to 130 of about 97,726 (142)

Anti-John Cunningham Virus antibody prevalence in multiple sclerosis patients in Turkey

2013
Exposure to John Cunningham Virus (JCV) has been associated with Progressive Multifocal Leukoencephalopathy (PML) in Multiple Sclerosis (MS) patients under specific treatments. In order to assess the identifiable risks of Turkish relapsing-remitting multiple sclerosis (RRMS) patients, the seroprevalence rate of JCV antibodies was investigated and ...
ERAKSOY, Mefkure, AGAN, Kadriye, AK, Fikri, ANLAR, Omer, BALCI, Belgin, BOZ, Cavit, CELIK, Yahya, DEMIRKAYA, Seref, EFENDI, Husnu, GECIZLIOGLU, Muhtesem, GUNAL, Dilek, AYDIN GUNGOR, Hulya, ISIK, Nihal, IDILMAN, Egemen, KARABUDAK, Rana, KURNE, Aslı, NEYAL, Munife, OZAKBAS, Serkan, EKMEKCI OZBAY, Ozgul, OZCAN, Cemal, OZTEKIN, Nese, OZTURK, Musa, SAIP, Sabahattin, SIVA, Aksel, SOYSAL, Aysun, TASKAPILIOGLU, Ozlem, TERZI, Murat, TURAN, Omer, TURKOGLU, Recai, YUCEMEN, Nezih, YUCEYAR, Ayse, ZORLU, Yasar, ULKU, Cunay, DIB, Huseyin, UREN, Deniz   +34 more
openaire   +1 more source

John Cunningham Virus (JCV) in Renal Allograft Recipients (RAR)

Journal of the American Society of Nephrology, 2020
Bushra Z. Saleem, Sonika Puri, Zahidul H. Mondal   +2 more
openaire   +1 more source

Cervical cancer prevention and control in women living with human immunodeficiency virus

Ca-A Cancer Journal for Clinicians, 2021
Philip E Castle, Vikrant V Sahasrabuddhe
exaly  

Assay selection affects John Cunningham virus serostatus classification in multiple sclerosis

Annals of Neurology, 2012
Joel B, Raffel, David, Hunt, Joanne, Topping, John, Bremner, Kevin E, Brown, Gavin, Giovannoni   +5 more
openaire   +2 more sources

Low seropositive John Cunningham virus (JCV) profile in a Northeast Brazilian Natalizumab MS treated population: differences comparing with global data.

Proceedings of the BCTRIMS 24th Annual Meeting, 2023
I. Santiago, I. Nóbrega, L. S. Mendes, G. Martins, J. A. d’Almeida, M. Pitombeira   +5 more
semanticscholar   +1 more source

Assay design and sample collection can affect anti‐John Cunningham virus antibody detection

Annals of Neurology, 2011
Susan E. Goelz, Leonid Gorelik, Meena Subramanyam   +2 more
openaire   +1 more source

Medical devices; immunology and microbiology devices; classification of John Cunningham Virus serological reagents. Final order.

Federal register, 2014
The Food and Drug Administration (FDA) is classifying John Cunningham Virus (JCV) serological reagents into class II (special controls). The Agency is classifying the device into class II (special controls) in order to provide a reasonable assurance of safety and effectiveness of the device.
openaire   +1 more source

The oncologic burden of hepatitis C virus infection: A clinical perspective

Ca-A Cancer Journal for Clinicians, 2017
Harrys A Torres, Roy F Chemaly, Nassim Hammoudi   +2 more
exaly  

The prevalence of John Cunningham virus antibody positivity in psoriasis

Journal of the American Academy of Dermatology, 2019
openaire   +1 more source

Distribution and Quantity of Sites of John Cunningham Virus Persistence in Immunologically Healthy Patients

JAMA Neurology, 2017
Joseph R Berger, Craig Miller, Elizabeth B Norton   +2 more
exaly